Merck’s investigational KRAS G12C inhibitor, calderasib, is making headlines not for its standalone potency but for a strategically different attribute:…
Read More

Merck’s investigational KRAS G12C inhibitor, calderasib, is making headlines not for its standalone potency but for a strategically different attribute:…
Read More